免疫检查点抑制剂常见免疫相关不良反应及其管理

doi:10.3760/cma.j.cn371439-20200828-00020

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (2): 105-108.doi: 10.3760/cma.j.cn371439-20200828-00020

免疫检查点抑制剂常见免疫相关不良反应及其管理

李慧, 杨宇()

哈尔滨医科大学附属第二医院肿瘤内科 150000

收稿日期:2020-08-28 修回日期:2020-09-20 出版日期:2021-02-08 发布日期:2021-03-11
通讯作者: 杨宇 E-mail:yangyu13836125585@163.com

Common immune-related adverse reactions of immune checkpoint inhibitors and their management

Li Hui, Yang Yu()

Department of Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin 150000, China

Received:2020-08-28 Revised:2020-09-20 Online:2021-02-08 Published:2021-03-11
Contact: Yang Yu E-mail:yangyu13836125585@163.com

摘要/Abstract

摘要：

目前临床上免疫检查点抑制剂(ICI)应用广泛,常见的不良反应包括皮肤、胃肠道、内分泌和肝脏不良反应,肺脏和心脏不良反应相对较少,但可能致命。类固醇全身治疗是对抗免疫治疗相关不良反应(irAE)的主要治疗手段,如对类固醇治疗没有反应,则需要考虑使用免疫调节剂。掌握irAE的发生率、发病机制、常见类型及其治疗策略,可为ICI在临床上的安全应用提供理论依据。

关键词: 肿瘤, 免疫检查点抑制剂, 免疫治疗相关不良反应, 治疗策略

Abstract:

At present, immune checkpoint inhibitors (ICIs) are widely used in clinical, and the common adverse reactions include adverse reactions of skin, gastrointestinal tract, endocrine and liver. Adverse reactions to the lungs and heart are relatively rare, but can be fatal. Systemic steroid therapy is the main treatment for immune related adverse events (irAEs). If there is no response to steroid therapy, an immunomodulator may be considered. Understanding the incidence, pathogenesis, common types and treatment strategies of irAEs can provide theoretical basis for the safe application of ICIs in clinical practice.

Key words: Neoplasms, Immune checkpoint inhibitor, Immune related adverse events, Treatment strategy

李慧, 杨宇. 免疫检查点抑制剂常见免疫相关不良反应及其管理[J]. 国际肿瘤学杂志, 2021, 48(2): 105-108.

Li Hui, Yang Yu. Common immune-related adverse reactions of immune checkpoint inhibitors and their management[J]. Journal of International Oncology, 2021, 48(2): 105-108.

参考文献 17

[1]	Inno A, Metro G, Bironzo P, et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity[J]. Tumori, 2017,103(5):405-421. DOI: 10.5301/tj.5000625. doi: 10.5301/tj.5000625 pmid: 28497847
[2]	Zhou X, Yao Z, Yang H, et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis[J]. BMC Med, 2020,18(1):87. DOI: 10.1186/s12916-020-01549-2. doi: 10.1186/s12916-020-01549-2 pmid: 32306958
[3]	Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade[J]. Cancer, 2017,123(S11):2143-2153. DOI: 10.1002/cncr.30444. doi: 10.1002/cncr.30444 pmid: 28543699
[4]	Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglo-bulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018,109(11):3583-3590. DOI: 10.1111/cas.13800. doi: 10.1111/cas.13800 pmid: 30230649
[5]	Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody[J]. Sci Transl Med, 2014,6(230):230ra45. DOI: 10.1126/scitranslmed.3008002. doi: 10.1126/scitranslmed.3008002 pmid: 24695685
[6]	Baban B, Liu JY, Qin X, et al. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153[J]. PLoS One, 2015,10(4):e0124059. DOI: 10.1371/journal.pone.0124059. doi: 10.1371/journal.pone.0124059 pmid: 25902191
[7]	Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma[J]. J Clin Oncol, 2017,35(7):785-792. DOI: 10.1200/JCO.2015.66.1389. doi: 10.1200/JCO.2015.66.1389 pmid: 28068177
[8]	Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor[J]. Eur J Cancer, 2016,60:12-25. DOI: 10.1016/j.ejca.2016.02.010. doi: 10.1016/j.ejca.2016.02.010 pmid: 27043866
[9]	Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016,4(5):383-389. DOI: 10.1158/2326-6066.CIR-15-0123. doi: 10.1158/2326-6066.CIR-15-0123 pmid: 26928461
[10]	Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes[J]. Clin Cancer Res, 2016,22(4):886-894. DOI: 10.1158/1078-0432.CCR-15-1136. doi: 10.1158/1078-0432.CCR-15-1136 pmid: 26446948
[11]	Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events[J]. J Am Acad Dermatol, 2014,71(1):161-169. DOI: 10.1016/j.jaad.2014.02.035. doi: 10.1016/j.jaad.2014.02.035
[12]	Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016,13(8):473-486. DOI: 10.1038/nrclinonc.2016.58. doi: 10.1038/nrclinonc.2016.58 pmid: 27141885
[13]	Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)[J]. Lancet, 2017,390(10105):1853-1862. DOI: 10. 1016/S0140-6736(17)31601-X. pmid: 28822576
[14]	De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J]. Cancer Immunol Res, 2017,5(4):312-318. DOI: 10.1158/2326-6066.CIR-16-0237. doi: 10.1158/2326-6066.CIR-16-0237 pmid: 28246107
[15]	Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management[J]. ESMO Open, 2018,3(1):e000278. DOI: 10.1136/esmoopen-2017-000278. doi: 10.1136/esmoopen-2017-000278 pmid: 29387476
[16]	Rajha E, Chaftari P, Kamal M, et al. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy[J]. Gastroenterol Rep (Oxf), 2019,8(1):25-30. DOI: 10.1093/gastro/goz065.
[17]	Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015,372(26):2521-2532. DOI: 10.1056/NEJMoa1503093. doi: 10.1056/NEJMoa1503093 pmid: 25891173

免疫检查点抑制剂常见免疫相关不良反应及其管理

Common immune-related adverse reactions of immune checkpoint inhibitors and their management

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 17

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.